Pharmaceutical

Sentynl acquires Eiger’s Zokinvy for progeria treatment

Sentynl Therapeutics has announced the acquisition of Zokinvy programme from Eiger BioPharmaceuticals for the treatment of progeria.

May 7, 2024 - 00:00
Sentynl acquires Eiger’s Zokinvy for progeria treatment
Sentynl Therapeutics has announced the acquisition of Zokinvy programme from Eiger BioPharmaceuticals for the treatment of progeria.
Read the original article

Tags:

Previous Article

UK MHRA approves ViiV Healthcare’s cabotegravir formulations for HIV-1

Next Article

Amgen reports a 22% increase in Q1 2024 net revenues

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Adcendo and Multitude ink ADC deal potentially worth $1bn

Adcendo and Multitude ink ADC deal potentially worth $1bn

Aug 21, 2024

Boehringer and 3T Biosciences partner to develop cancer immunotherapies

Boehringer and 3T Biosciences partner to develop cancer...

Jan 5, 2024

STAT+: Ohio attorney general accuses pharmacy benefit managers of drug price fixing

STAT+: Ohio attorney general accuses pharmacy benefit m...

Mar 28, 2023